Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


JADO secures EUR 3.9 million in Series B financing


Dresden, Germany, November 11, 2008 -- JADO Technologies GmbH, the leading developer of RAFT intervention therapeutics, announced today that it has raised EUR 3.9 million in a series B financing led by PEPPERMINT.Financial Partners. New investor NRW.BANK and existing investors Dresden Fonds GmbH, EMBL Ventures, KfW (ERP-Startfonds), Max Planck Society and MASA Life Science Ventures also participated in the round.

The proceeds will be used to advance two formulations of JADO’s lead clinical-stage compound, TF002, through the rest of Phase II trials in both atopic dermatitis and urticaria. Furthermore, the proceeds will be used to advance second generation allergy compounds to proof of principle in animal in asthma.

“We are convinced of the high growth potential for JADO. Our investment provides the necessary finances to establish a subsidiary in Bonn focusing on in-silico RAFT drug discovery. By starting this cooperation with the University of Bonn, the region North Rhine-Westphalia can deliver a sustainable contribution to further strengthen this revolutionary technology platform,” Ernst Gerlach, board member of NRW.BANK noted.

Concurrent with the financing, JADO has established an in-silico laboratory at the Department of Life Science Informatics, University of Bonn. The laboratory will develop an algorithm based filtering tool to screen compound libraries for new scaffolds with RAFT modulator activity. In-silico tools offer several advantages over classical approaches in identifying new scaffolds and options for intellectual property, including speed, efficiency and hit-rate. JADO believes this approach will generate new NCE classes and drug candidates during 2009.

“The continued support from investors, both new and existing, in JADO’s unique approach for finding therapeutics targeting RAFT is very encouraging, particularly in these tough funding conditions. The financing will allow us to complete Phase II clinical development of our lead compound, TF002, and take additional candidates into the preclinical stage,” stated Charl van Zyl, CEO of JADO. “We believe the RAFT mechanism is far-reaching and can be applied in several therapeutic areas. Many existing compounds have activity in lipid membrane, hence potentially against RAFT. So, we are looking not only to discover completely new molecules but also establish a library of existing compounds that we could quickly modify and enter into development.”

About RAFTS
RAFTS are discrete sub-compartments in the lipid membrane of cells that play a central role in the complex physiological processes, such as immune response or in many pathological situations. In an infectious disease event, RAFTS are hijacked by pathogens to gain entry into cells. By blocking this process, JADO is pursuing the development of novel therapeutics.

About JADO Technologies
JADO is a leader in the emerging field of RAFT intervention therapeutics. Representing a paradigm shift in drug development, RAFT therapeutics have the potential to address multiple unmet needs, particularly in allergy, infectious diseases, Alzheimer's disease and cancer.

RAFTS are sub-compartments of cell membranes that play an integral role in key biological pathways. The Company's RAFT Intervention Technology® provides a unique platform, protected by a strong patent position, to drive significant pipeline development opportunities. JADO has leveraged its technology to generate multiple small molecule drug candidates, with its lead program in Phase IIa clinical trials for allergy indications. The Company is supported by a global network of clinical and academic experts, including JADO founders, Prof. Kai Simons, Prof. Marino Zerial, Dr. Teymuras Kurzchalia (Max-Planck Institute of Molecular Cell Biology and Genetics, Dresden) and Prof. Hans-Joachim Knölker (Technical University of Dresden). JADO is headquartered in Dresden, Germany. For more information, please visit our website: www.jado-tech.com.

About NRW.BANK
NRW.BANK is the development bank of the State of North Rhine-Westphalia. Its four business segments are Promotion of Business Start-ups and SMEs, Municipal and Infrastructure Financing, Social Housing Promotion and Individual Promotion. For business start-ups and SMEs in North Rhine-Westphalia, NRW.BANK uses customised public promotion and equity finance products. The Bank aims to constantly improve the financing situation of this target group in line with actual requirements.

Contacts:
JADO Technologies Halsin Partners
Charl van Zyl, CEO Mike Sinclair, Director
+49 (0) 351 796 3800 +44 (0)20 7084 5955


Publisher Contact Information:

Halsin Partners
+44 (0)20 7084 5955
msinclair@halsin.com

Company profile of JADO Technologies
Past press releases of JADO Technologies.

Data


26,416
Tech investments
From our Online Data Service
17,054
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 30€3.6MSoftware development
Nov 29€3.6MBiopharmaceuticals
Nov 28N/ABiotechnology
Nov 28N/ABusiness applications
Nov 28€12.0MPublishing
Nov 28N/AeLearning
Nov 28€7.6MSensors

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.